Peregrine Pharmaceuticals (NASDAQ:PPHM)‘s stock had its “buy” rating reiterated by research analysts at Noble Financial in a research note issued to investors on Tuesday.

PPHM has been the topic of several other research reports. ValuEngine lowered shares of Peregrine Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, September 1st. Zacks Investment Research upgraded shares of Peregrine Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, November 18th.

Peregrine Pharmaceuticals (PPHM) opened at $4.20 on Tuesday. Peregrine Pharmaceuticals has a fifty-two week low of $1.96 and a fifty-two week high of $5.78.

Peregrine Pharmaceuticals (NASDAQ:PPHM) last announced its quarterly earnings data on Monday, September 11th. The biopharmaceutical company reported ($0.06) earnings per share for the quarter, beating the consensus estimate of ($0.12) by $0.06. Peregrine Pharmaceuticals had a negative net margin of 39.23% and a negative return on equity of 50.72%. The firm had revenue of $27.08 million for the quarter, compared to analyst estimates of $15.22 million. sell-side analysts forecast that Peregrine Pharmaceuticals will post -0.43 earnings per share for the current year.

Several hedge funds and other institutional investors have recently made changes to their positions in PPHM. Ballentine Partners LLC acquired a new stake in shares of Peregrine Pharmaceuticals in the 2nd quarter worth about $113,000. Wells Fargo & Company MN raised its holdings in shares of Peregrine Pharmaceuticals by 48.0% in the 2nd quarter. Wells Fargo & Company MN now owns 338,378 shares of the biopharmaceutical company’s stock worth $206,000 after acquiring an additional 109,750 shares during the last quarter. JPMorgan Chase & Co. raised its holdings in shares of Peregrine Pharmaceuticals by 140.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 72,069 shares of the biopharmaceutical company’s stock worth $224,000 after acquiring an additional 42,069 shares during the last quarter. OxFORD Asset Management LLP acquired a new stake in shares of Peregrine Pharmaceuticals in the 3rd quarter worth about $231,000. Finally, Northern Trust Corp raised its holdings in shares of Peregrine Pharmaceuticals by 9.3% in the 2nd quarter. Northern Trust Corp now owns 454,451 shares of the biopharmaceutical company’s stock worth $276,000 after acquiring an additional 38,604 shares during the last quarter. Hedge funds and other institutional investors own 18.88% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This news story was first reported by Watch List News and is the sole property of of Watch List News. If you are accessing this news story on another domain, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be accessed at https://www.watchlistnews.com/peregrine-pharmaceuticals-pphm-stock-rating-reaffirmed-by-noble-financial/1762582.html.

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc (Peregrine) is a biopharmaceutical company. The Company operates through two segments: Peregrine, which is engaged in the research and development of monoclonal antibodies for the treatment of cancer, and Avid, which is engaged in providing contract manufacturing services for third party customers on a fee-for-service basis while also supporting its internal drug development efforts.

Receive News & Ratings for Peregrine Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Peregrine Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.